Is Entera Bio Ltd. (ENTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 15.1% / 30% | 0.2% / 30% | 0.0% / 5% | ✓ HALAL |
| DJIM | 0.5% / 33% | 15.1% / 33% | 0.2% / 33% | 0.0% / 5% | ✓ HALAL |
| MSCI | 2.9% / 33% | 92.2% / 33% | 1.3% / 33% | 0.0% / 5% | ✗ NOT HALAL |
| S&P | 0.5% / 33% | 15.1% / 33% | 0.2% / 33% | 0.0% / 5% | ✓ HALAL |
| FTSE | 2.9% / 33% | 92.2% / 33% | 1.3% / 50% | 0.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -8729.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -99.4% | |
| Return on Assets (ROA) | -53.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $272,000 |
| Debt-to-Equity | 1.4 |
| Current Ratio | 10.8 |
| Total Assets | $9M |
Price & Trading
| Last Close | $1.03 |
| 50-Day MA | $1.38 |
| 200-Day MA | $1.91 |
| Avg Volume | 200K |
| Beta | 1.5 |
|
52-Week Range
$0.98
| |
About Entera Bio Ltd. (ENTX)
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Entera Bio Ltd. (ENTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Entera Bio Ltd. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Entera Bio Ltd.'s debt ratio?
Entera Bio Ltd.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.9%.
What are Entera Bio Ltd.'s key financial metrics?
Entera Bio Ltd. has a market capitalization of $52M, and revenue of $181,000. Return on equity stands at -99.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.